May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
A Breast Cancer Risk Assessment Tool That Includes Breast Density Measures
Distinct Molecular Tumor Profile in Younger CRC Patients Recognized